An AOD-9604 dosage protocol in research settings usually means 1 mg injected once daily. See study doses, 5 mg vial math, and key safety facts.
There is no FDA-approved AOD-9604 dosage protocol for human use. In published research, the most common approach is 1 mg injected subcutaneously once daily, often in a fasted state, for roughly 12 weeks. Study doses have ranged from about 300 mcg to 1 mg per day; higher amounts come from anecdote, not controlled clinical trials.
AOD-9604 is a synthetic peptide fragment of human growth hormone that matches amino acids 176-191 of the HGH molecule. Researchers developed it in Australia to target fat metabolism without the growth-promoting or blood sugar effects of full HGH. Today it is sold as a research chemical rather than an approved medicine, so purity and actual content vary by vendor.
What AOD-9604 Is and Why Dosing Is Uncertain
AOD-9604 was studied in humans as an anti-obesity candidate in the 2000s. Laboratory work suggested it could stimulate lipolysis and inhibit fat storage, and early human trials showed a trend toward fat loss.
No regulatory agency has approved it, and the human dataset is small. That is the core reason no official dosing standard exists: there simply are not enough controlled studies to establish one.
Reported AOD-9604 Dosage Protocol Patterns
The table below summarizes the patterns that appear most often in study summaries and community write-ups. A typical aod 9604 dosage protocol uses one injection per day at a consistent time.
| Protocol style | Daily dose | Frequency | Route | Typical duration |
|---|---|---|---|---|
| Human obesity trial | 1 mg | Once daily | Subcutaneous | 12 weeks |
| Lower-dose protocol | 300-500 mcg | Once daily | Subcutaneous | 8-12 weeks |
| Split-dose protocol | 500 mcg | Twice daily | Subcutaneous | Not studied in humans |
| Oral or sublingual | 1 mg or more | Once or twice daily | Mouth | Not studied in humans |
The pattern is worth noting. The only human evidence that exists is for 1 mg once daily by subcutaneous injection. Split doses, sublingual drops, and oral capsules are widely discussed online but have not been validated in controlled human research.
AOD-9604 Dosage Per Day for Weight Loss: What Trials Showed
An aod-9604 dosage per day for weight loss of 1 mg produced modest results at best. In the largest human trial, participants on the peptide lost slightly more weight than those on placebo, but the difference did not reach statistical significance for the primary endpoint, and the developer shelved the obesity program.
Secondary data did point to small reductions in fat mass and some improvements in lipid markers. Those signals explain why interest in the peptide has persisted despite the disappointing headline results.
To be direct: AOD-9604 is not an FDA-approved weight loss drug, and no dose has been proven to produce meaningful, lasting fat loss in people. Any change in body weight should be judged alongside diet, activity, sleep, and routine clinical care.
Reconstitution, 5 mg Vial Math, and Storage
Most AOD-9604 ships as a lyophilized powder in a 5 mg vial. Correct aod-9604 reconstitution and dosage begins with adding bacteriostatic water slowly down the inside wall of the vial, then swirling gently. Shaking or vigorous mixing can damage the peptide.
After mixing, refrigerate the vial at 2-8 C, protect it from light, and use it within a few weeks. Unreconstituted powder stays stable far longer when kept cold and dry.
Working Out an AOD-9604 5 mg Dosage
An aod 9604 5mg dosage is easiest to calculate once you know your dilution ratio. The table below shows the draw volume on a standard U-100 insulin syringe.
| Diluent added to a 5 mg vial | Concentration | 1 mg draw | 500 mcg draw | 300 mcg draw |
|---|---|---|---|---|
| 1 mL | 5 mg/mL | 0.2 mL (20 units) | 0.1 mL (10 units) | 0.06 mL (6 units) |
| 2 mL | 2.5 mg/mL | 0.4 mL (40 units) | 0.2 mL (20 units) | 0.12 mL (12 units) |
| 3 mL | 1.67 mg/mL | 0.6 mL (60 units) | 0.3 mL (30 units) | 0.18 mL (18 units) |
| 5 mL | 1 mg/mL | 1 mL (100 units) | 0.5 mL (50 units) | 0.3 mL (30 units) |
More diluent makes small doses easier to measure accurately, but it also means a larger injection volume. Someone targeting 1 mg from a 5 mg vial will usually choose 1 mL or 2 mL of diluent to keep the draw practical.
Dosing for Men vs. Women and Route Options
There is no evidence that an aod 9604 dosage for men needs to differ from female dosing. Human trials enrolled both sexes and used the same 1 mg daily injection for everyone.
Body weight, injection technique, and overall health matter far more than sex when estimating a dose. Any protocol should be reviewed with a clinician who knows your medical history and current medications.
Injection vs. Oral vs. Sublingual
| Route | Human evidence | Reported dose | Notes |
|---|---|---|---|
| Subcutaneous injection | Yes, clinical trials | 1 mg once daily | Best-characterized route; used in all human studies |
| Sublingual drops | No | 1 mg held under the tongue | Absorption and stability are unverified |
| Oral capsule | No | 1 mg or more daily | Likely broken down during digestion |
| Nasal spray | No | Not established | No data specific to AOD-9604 |
Only the subcutaneous route has been studied in humans. Everything else is speculative and should not be treated as equivalent.
Safety, Legal Status, and Key Takeaways
- AOD-9604 is not FDA-approved for human use in the United States and is sold as a research chemical.
- The World Anti-Doping Agency lists AOD-9604 as a prohibited substance for athletes.
- Reported side effects in trials were mild and included injection site irritation, headache, and nausea.
- Safety data beyond roughly 12 weeks of use are essentially absent.
Peptides purchased outside a licensed pharmacy are not guaranteed to be sterile, pure, or correctly labeled. Anyone considering AOD-9604 should discuss it with a healthcare professional and weigh unproven benefits against unknown long-term risks.
Three conclusions matter most. The most studied AOD-9604 dose is 1 mg once daily by subcutaneous injection. Weight loss results in human trials were not statistically significant. No AOD-9604 product is approved for human use in the United States.
Frequently Asked Questions
What is the typical AOD-9604 dosage per day?
The most commonly cited research dose is 1 mg injected subcutaneously once daily, usually for about 12 weeks. Lower amounts of 300 to 500 mcg per day appear in some protocols, but only the 1 mg daily injection has been formally studied in humans. No dose is FDA-approved.
How do you reconstitute a 5 mg vial of AOD-9604?
Add 1 to 2 mL of bacteriostatic water slowly down the inside wall of the vial and swirl gently instead of shaking. With 2 mL of diluent, a 5 mg vial yields 2.5 mg/mL, so a 1 mg dose equals 0.4 mL, or 40 units on a U-100 insulin syringe.
Is AOD-9604 legal or FDA-approved?
No. AOD-9604 is not FDA-approved for human use in the United States and is sold only as a research chemical. It also appears on the WADA prohibited list, so athletes subject to drug testing should avoid it.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.